Supplemental vitamin A and nicotinamide for kidney transplant recipients at high risk of skin cancer
Official title: Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide
Run by Rhode Island Hospital · NCT05702398 · Data updated 2026-11-12
This pilot will test whether taking oral nicotinamide and vitamin A is safe and doable for kidney transplant recipients who have had recent skin cancers.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Rhode Island Hospital Academic / other |
| Locations | 1 site (Providence, Rhode Island) |
| Status | Recruiting |
| Started | April 1, 2023 |
| Main results expected | January 1, 2028 |
| Study ends | March 1, 2028 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT05702398 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who have received a kidney transplant and have a recent history of multiple invasive cutaneous squamous cell carcinomas or extensive treated premalignant skin lesions are the intended participants.
✕Probably not a fit
People with active liver disease, recent myocardial infarction, eGFR <15 mL/min/1.73 m2, pregnancy or lactation, genetic skin cancer syndromes, very large numbers of current skin cancers, metastatic SCC or recent invasive melanoma, or those taking interacting drugs like carbamazepine are not likely to be eligible or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase pilot enrolls adult kidney transplant recipients with a recent history of multiple cutaneous squamous cell carcinomas or extensive treated premalignant lesions. Participants will take oral nicotinamide and vitamin A or a matching placebo while investigators monitor safety, tolerability, and adherence. The trial excludes people with significant liver disease, recent myocardial infarction, certain medication interactions, very low kidney function, pregnancy, or genetic skin cancer syndromes. Findings will provide preliminary safety and feasibility data to guide larger cancer prevention trials in this high-risk population.
Why it matters
Potential benefit: If successful, the regimen could reduce future skin cancers in transplant recipients and support larger prevention trials.
How similar studies have gone: Oral nicotinamide has reduced new nonmelanoma skin cancers in other high-risk groups, but the combination with vitamin A in kidney transplant recipients is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or greater; * Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or * At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system); * Understands, reads, and writes English proficiently. Exclusion Criteria: * Liver disease; * Active peptic ulcer disease; * Recent myocardial infarction; * Hypotension; * Internal malignancy within past 5 years; * Renal impairment with eGFR\<15 mL/min/1.73 m2; * Being unable for follow up due to social reasons; * Gorlin's syndrome or other genetic skin cancer syndrome; * Huge number of current skin cancers; * Metastatic SCC or invasive melanoma within the past 5 years; * Pregnancy or lactation; * Need for ongoing carbamazepine use (which could have a possible interaction with NAM); * Use of acitretin or other oral retinoids within the past 6 months; * Use of supplemental NAM, niacin, vitamin A, or beta carotene within the past 6 months; * Field treatment for actinic keratoses (AKs) within the previous 4 weeks; * Use of topical steroids.
Where it's running
-
Rhode Island Hospital
Providence, Rhode Island, United States Recruiting
Study contacts
- Study coordinator: Eunyoung Cho, ScD
- Email: Eunyoung_Cho@brown.edu
- Phone: 401-863-5895
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mobile sun protection support to help young adults stay safe in the sun
This project tests a mobile health program to see if reminders, education, planning tools, and real-time sun exposure information can help young adults protect their skin from excessive sun exposure.
-
Diode laser–assisted gum treatment for people with kidney transplants
This project will test whether adding a diode laser to standard deep dental cleaning (scaling and root planing) helps people with periodontitis who have had a kidney transplant.
-
Psycho-physiological profiling of people with low versus high heat resilience
This project will test whether controlled heat and UV exposures plus physiological and psychological measurements can identify healthy adults who are more or less resilient to heat.
-
Cosibelimab for tough CSCC in kidney transplant recipients or blood cancers
This trial tests cosibelimab in people with advanced cutaneous squamous cell carcinoma who have a kidney transplant or certain blood cancers to see if it is safe and helpful for them.
-
First-line immunotherapy and PD-L1 testing for metastatic melanoma in Slovenia
This study will see if first-line immunotherapy (pembrolizumab, nivolumab, or ipilimumab plus nivolumab) works for adults in Slovenia with metastatic melanoma and whether PD-L1 measurements predict who responds.
-
Optical and multi-modal analysis to help diagnose skin cancer
This project tests whether combining optical spectroscopy and imaging data from skin samples can help diagnose skin cancer in people with skin concerns.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.